| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3640 |
| Trial ID | NCT06104592 |
| Disease | Large B-Cell Lymphoma | Relapsed Non-Hodgkin's Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Axi-Cel|Relma-cel|Axicabtagene Ciloleucel|JWCAR029|relmacabtagene autoleucel|Yescarta |
| Location approved | China |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | Phase 2, Single-Arm Trial of Comprehensive Ablative Bridging Irradiation (CABI) Prior to CD19 CAR-T Cell Therapy in High-Risk, Relapsed or Refractory Large B Cell Lymphoma in Patients With Bulky Disease |
| Year | 2023 |
| Country | United States |
| Company sponsor | H. Lee Moffitt Cancer Center and Research Institute |
| Other ID(s) | MCC-22113 |
| Cohort 1 | |||||||||
|
|||||||||